Erratum: Genomics drugs in clinical trials (Nature Reviews Drug Discovery (2010) 9 (988) DOI:10.1038/nrd1552-c1);Genomics drugs in clinical trials

Nature Reviews Drug Discovery

Volumn 9, Issue 12, 2010, Pages 988-

  Hall, Jonathan ^a   Dennler, Patrick ^a   Haller, Stephanie ^a   Pratsinis, Anna ^a   Säuberli, Katharina ^a   Towbin, Harry ^a   Walthe, Katja ^a   Woytschak, Janine ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 785; ANTINEOPLASTIC AGENT; APOMAB; ATACICEPT; BELIMUMAB; DG 041; DULANERMIN; G PROTEIN COUPLED RECEPTOR; LX 1031; LX 1032; MAPATUMUMAB; OC 000459; ODANACATIB; PLX 4032; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ASTHMA; B LYMPHOCYTE; BINDING AFFINITY; CARCINOID SYNDROME; CLINICAL RESEARCH; CLINICAL TRIAL; DIGESTIVE SYSTEM INFLAMMATION; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; HUMAN; IRRITABLE COLON; LETTER; MELANOMA; NEOPLASM; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACOGENOMICS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; RESPIRATORY TRACT DISEASE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSGENE; TREATMENT INDICATION;

EID: 78649694445     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3382     Document Type: Erratum

References (25)

1. Kramer, R. & Cohen, D. Functional genomics to new drug targets. Nature Rev. Drug Discov. 3, 965-972 (2004) .
2. Editorial. The human genome at ten. Nature 464, 649-650 (2010).
3. Garnier, J.-P. Rebuilding the R&D engine in big pharma. Harv. Bus. Rev. 86, 68-76 (2008).
4. Dall'Era, M. & Wofsy, D. Connective tissue diseases: belimumab for systemic lupus erythematosus: breaking through? Nature Rev. Rheumatol. 6, 124-125 (2010).
5. Moore, P. A. et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260-263 (1999)
6. Mackay, F., Schneider, P., Rennert, P. & Browning, J. BAFF and APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231-264 (2003). (Pubitemid 37174532)
7. Furie, R. et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res. Ther. 10, R109 (2008).
8. Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res. 61, 1168-1178 (2009).
9. Gross, J. A. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995-999 (2000).
10. Nestorov, I., Papasouliotis, O., Pena Rossi, C. & Munafo, A. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J. Pharm. Sci. 99, 524-538 (2010).
11. Pan, G. et al. The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113 (1997).
12. Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821 (1997).
13. Wiley, S. R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682 (1995).
14. Moretto, P. & Hotte, S. J. Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1. Expert Opin. Investig. Drugs 18, 311-325 (2009).
15. Fox, N. E., Humphreys, R., Luster, T. A., Klein, J. & Gallant, G. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy. Expert Opin. Biol. Ther. 10, 1-18 (2010).
16. Kometani, M., Kazuhiko, N., Tomoo, T. & Niwa, S. Hurdles in the drug discovery of cathepsin K inhibitors. Curr. Top. Med. Chem. 10, 733-744 (2010).
17. Bone, H. G. et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937-947 (2010).
18. Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577-589 (2001).
19. Padhi, D., Jang, G., Stouch, B., Fang, L. & Posvar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 30 Jun 2010 (doi:10.1002/jbmr.173).
20. Gudmundsson, G. et al. Localization of a gene for peripheral arterial occlusive disease to chromosome 1p31. Am. J. Hum. Genet. 70, 586-592 (2002).
21. Pettipher, R., Mangion, J., Hunter, M. G. & Mackay, I. Identification of G-protein-coupled receptors involved in inflammatory disease by genetic association studies. Curr. Opin. Pharmacol. 5, 412-417 (2005).
22. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
23. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
24. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
25. Yu, X., Miranda, M. & Hu, Y. Protein and cDNA sequence of human tryptophan hydroxylase homologs. WO2002097039 (2002).